Off-patent drugs are supposed to be “easy”—until you try to source them at scale.
In practice, the hardest part isn’t finding an API supplier. It’s finding a qualified supplier you can trust across regulatory, quality, and documentation—while staying f…

Pharma IP teams don’t lose deals because they lack patents. They lose them because the work behind the patents is mismanaged.
That’s the uncomfortable truth hiding in plain sight: in modern drug development, “project management” isn’t an operational af…

Your drug’s patent just expired. That moment feels like a cliff—until you realize it’s a lifecycle.
In pharma, “patent expiration” is rarely a single event. It’s the visible edge of a much longer timeline: exclusivity windows, regulatory milestones, ma…

How Do Entyvio and Humira Work for Crohn’s? Entyvio (vedolizumab) targets integrin receptors on gut-specific white… https://www.Drugchatter.com/chat/15639/is-entyvio-better-than-humira-for-crohn’s-disease/

How Do Entyvio and Humira Work for Crohn’s? Entyvio (vedolizumab) targets integrin receptors on gut-specific white… https://www.Drugchatter.com/chat/15639/is-entyvio-better-than-humira-for-crohn’s-disease/

Drug patents in Africa: exactly how long they last—and why it matters more than ever
If you’ve ever wondered why some medicines seem to arrive late, cost more than expected, or remain out of reach for years, the answer is often hiding in plain sight: p…

🚦 Green light to launch: the definitive step-by-step FTO analysis guide is here—and it could change how new drug products get to market.
In pharma, the hardest part isn’t always the science. It’s the risk math—the moment you ask: Can we launch witho…

Biotech investors don’t lose money because they can’t read the science. They lose money because they overpay for the wrong signals.
Here’s the uncomfortable truth: most “value” frameworks in biotech are built on narratives—platform potential, pipeline …